OVARIAN SEROUS ADENOCARCINOMA

This study tested whether giving the chemotherapy drug paclitaxel weekly works better than the standard every-3-weeks schedule for people with advanced ovarian, peritoneal, or fallopian tube cancer. All participants also received carboplatin, and some received the targeted drug b…

This study tests a new treatment for ovarian cancer that has come back after standard therapy. It uses stem cells loaded with a modified measles virus to deliver cancer-killing effects directly into the abdomen. The trial involves 34 participants and aims to find the safest dose …

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer. About 88 newly diagnosed patients will receive either the drug combo or chemo alone before surgery. The main goa…

This study tested a combination of two drugs, cediranib and olaparib, in 155 people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer had come back. The goal was to see if the combo was safe and worked better than olaparib alone at slowing cancer growth.…

This study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…

This study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with ovarian, peritoneal, or fallopian tube cancer that has come back live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus beva…